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Chapter 2 Conformationally constrained cyclic peptides represent 





In this chapter, cyclic nonapeptides containing a disulfide bridge were identified as a 
simple and versatile coordination sphere for asymmetric catalysis. Upon complexation 
with Cu2+-ions they catalyze Diels-Alder reactions with high enantioselevities of up to 
91% ee. This biomolecular design could greatly expand the choice of peptide 
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Tremendous efforts have been devoted to the design of asymmetric artificial 
metalloenzymes based on the conception of introducing an achiral transition-metal 
complex into an existing protein scaffold via covalent or supramolecular 
interactions.[1] Several of these systems containing different host proteins, metals and 
ligands catalyzed several reactions with  excellent enantioselectivities.[2] However, 
this approach still faces some limitations. The host proteins are either costly compared 
to small chiral ligands or they need to be produced by recombinant expression and 
associated to that generation of larger libraries is still a difficult task.[3] In this respect, 
polypeptides are a suitable alternative since they are readily accessible by standard 
solid phase synthesis. Miller and coworkers reported a number of non-metal 
containing peptide catalysts that often exhibited excellent enantioselectivities of 
greater than 90%.[4] In contrast, oligo- and polypeptides were combined with metal 
ions to act as catalysts in enantioselective organic transformations employing natural 
aspartic acid side chains and non-natural amino acids with phosphine or pyridine 
functions for metal complexation.[5] The peptide scaffolds included metal chelating 
helical[5a] or β turn structures,[5b] oriented β turns,[5c] self-assembled β-sheet motifs[5d] 
and natural polypeptide folds.[5e,5f] However, peptide scaffolds with only little 
sequence constriction and large free choice of amino acid composition remain elusive. 
Moreover, most artificial metallopeptides require significant synthetic efforts. 
Herein we introduce a novel design of metallopeptides, which involves the formation 
of a stable cyclic peptide scaffold via an intramolecular disulfide linkage. In addition, 
our peptide ligand contained only natural amino acids avoiding synthesis of 
non-natural amino acids or elaborate post-modification protocols for metal 
coordination. Two types of peptide ligands were introduced, one binding the metal ion 
at the N-terminus and the other complexing the metal species via a histidine side 
chain. This strategy is characterized by synthetic simplicity and allows versatile 
structural variation and rapid optimization of the catalytic system. 
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2.2 Results and discussion 
2.2.1 Design and synthesis of peptide ligands 
As for the above-mentioned metallopeptides, our design strategy started with the 
generation of a peptide scaffold with a confined structure. Inspired by the widespread 
occurrence of disulfide bridges in proteins[6] and the fact that disulfide linkages 
stabilize specific peptide conformations,[7] we decided to use this structural element to 
fabricate peptide rings and evaluate their suitability in asymmetric catalysis (Figure 
2.1a). In the next step, anchoring sites for the metal ion needed to be defined. We 
decided to block the C-terminus by amidation to achieve selective metal coordination 
either at the amino group of the N-terminus or within the peptide backbone at the 
imidazole residue of histidine.[8] In case of binding to histidine we decided not to 
protect the N-terminus because of the well-known preferential binding to the aromatic 
heterocycle.[9] With this considerations in mind a small library of 15 cyclic 
nonapeptides was synthesized from which nine contained an internal histidine 
anchoring point (Figure 2.1b). Between the two terminal cysteines randomly picked 
amino acids were placed only avoiding sequences known to form secondary structures. 
The peptides were prepared by a commercial supplier by solid phase peptide synthesis, 
purified by C18 reversed phase HPLC, and characterized by MALDI-TOF mass 
spectrometry.[10]  
2.2.2 Diels-Alder reactions using cyclic peptide ligands 
With these peptides the Cu2+-catalyzed Diels-Alder (D-A) reaction of azachalcone (1) 
with cyclopentadiene (2) in aqueous medium[2d,5e,11] was pursued since this particular 
transformation is a good model to evaluate the selectivity of the potential 
metallopeptide catalysts. Previously, Engberts and co-workers applied this reaction 
with amino acids as ligands and achieved a maximum ee value of 74%.[11a] Out of our 
small library remarkably four sequences yielded an enantiomeric excess of more than 
30% ee underlining the potency of our selected scaffold for asymmetric catalysis 




and 35% ee, respectively, with L5 a good selectivity of 62% ee was achieved and 
application of L12 resulted in the highest enatiomeric excess (87%). L5 contains a 
histidine in the side chain and therefore we consider this position as the primary 
binding site for Cu2+ while in L12 metal complexation most probably occurs 
primarily at the N-terminal amine group.[8] Interestingly, these two ligands yielded 
both of the enantiomers.  
 
Figure 2.1. a) Schematic representation of the proposed cyclic peptide ligand with 
constrained conformation via intramolecular disulfide bridge. b) Screening of a cyclic peptide 
ligand library for D-A reaction. General conditions: 1 (0.6 μmol), 2 (24 μmol), Cu(NO3)2 
(15% mol), L (30% mol) in 20 mM 3-(N-morpholine) propanesulfonic acid buffer (MOPS) 
with pH = 6.5, for 3 days at 6 °C. All peptides are C-terminal –NH2 amides. 
We further investigated the effects of different reaction conditions on the identified 
ligands L5 and L12 exhibiting different metal binding modes. In general, the 
diastereoselectivity and enantioselectivity of L12 were higher than those of L5 (Table 
2.1). In both cases, the enantioselectivities of the reaction were found to be highly pH 
dependent. Decreasing the pH resulted in a significant decrease in the 
enantioselectivity, for instance, maximum ee values were obtained at pH of 6.5 (entry 
1), however, at pH = 4, the ee values dropped to nearly 0 (entry 2). This result can be 
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explained by the protonation of the primary binding sites which causes indiscriminate 
association of the copper ion to the peptides. Next, various buffer conditions were 
investigated and it turned out that the catalysts involving L5 and L12 are insensitive 
to buffer composition and ionic strength.(Experimental section, Table 2.4). As another 
important parameter the stoichiometry between ligands and metal ion were elucidated. 
A L/Cu2+ ion ratio of 2 or higher gave the best ee values; a ratio of less than 2 induced 
a progressive reduction in the ee values approaching 20% and 31% for L5 and L12 
(L/Cu2+ = 0.5), respectively (Experimental section, Figure 2.3). A decrease in the 
catalyst loading from 15 to 3 mol% led to only a slight drop of conversions but to a 
distinct reduction of ee values for both L5 and L12 (entry 3). Regarding the presence 
of different anions, similar results were obtained for Cu(NO3)2, CuCl2 and Cu(OTf)2 
indicating the minimal influence of the counterion on the selectivity (entries 1, 4 and 
5). In contrast, it was found that the cation plays a critical role in the artificial 
metallopeptide based catalysis. When ZnCl2 and Ni(NO3)2 were subjected to the D-A 
reaction in the presence of L5 or L12 (entry 6 and 7) very low conversions and 
enantioselectivities were observed. Finally, to rule out a possible catalysis by the 
pristine peptides, we repeated the reaction in the absence of Cu(NO3)2. Under 
otherwise identical conditions only slight conversions were observed and the major 
products were essentially racemic (entry 8). 
Table 2.1. Results of Diels-Alder reactions based on L5 and L12 
Entry Metal salt 
Conversion [%] 
L5 / L12 
Endo:exo 
L5 / L12 
ee(endo) [%][a] 
L5 / L12 
1 Cu(NO3)2 91 / 99 87:13/ 96:4 62 (2R,3R)/87(2S,3S) 
2[b] Cu(NO3)2 98 / 100 93:7/ 97:3 2 / 5 
3[c] Cu(NO3)2 75 / 89 84:16/ 93:7 41(2R,3R)/79 (2S,3S) 
4 CuCl2 92 / 96 88:12/ 96:4 60 (2R,3R)/86 (2S,3S) 
5[d] Cu(OTf)2 89 / 94  87:13/ 96:4 61 (2R,3R)/86 (2S,3S) 
6 ZnCl2 16 / 19 88:12/88:12 0 / 0 
7 Ni(NO3)2 41 / 47 87:13/87:13 0 / 4 
8[e] none 3 / 4 n.d. / n.d. 0 / 0 
General conditions : 1a (0.6 μmol), 2 (2 μL), metal ions (15% mol), L (30% mol) in 20 mM 
MOPS (pH 6.5), for 3 days at 6 °C. Data were obtained from the crude product on chiral 




[a] Absolute configuration were determined by comparison with the reported literature.[12] 
[b]Acetate buffer with pH = 4.0 was used instead of MOPS buffer (pH 6.5). [c] 3 mol% 
Cu(NO3)2 and 6 mol% peptides. [d] OTf = trifluoromethanesulfonate. [e] Not determined due 
to the low conversion. 
2.2.3 Effect of peptide ligands on the reaction rate 
To elucidate the catalytic activity further, the initial rate (Vinit) of the D–A reactions 
mediated by Cu2+, L5-Cu2+ and  L12-Cu2+ were measured from the initial decrease 
in absorption of 1a (Experimental section, Figure 2.4-2.7). Taking Vinit into account, 
the apparent second order rate constants (kapp) were determined.[11a, 11b] Free Cu(NO3)2 
increased kapp 12-fold (Table 2.2, entry 2) while complexes containing L5 and L12 
reacted slower than the free Cu2+ ion (entry 3 and 4). These rate differences combined 
with the high enantioselectivities induced by the complexes, indicate that the copper 
ion is strongly and specifically anchored on the peptides and they only act as a source 
of chirality for the reaction. Noteworthy, L5-Cu2+ catalyzed the reaction with a rate 
four times slower than L12-Cu2+ which is therefore only slightly faster than without 
any catalyst (entry 1).  In this case the background reaction might proceed in parallel 
with the metal complex mediated reaction, which can explain the lower ee values of 
L5-Cu2+ relative to L12-Cu2+.   
Table 2.2. kapp of the D-A reactions catalyzed by Cu2+, L5-Cu2+ and  L12-Cu2+  
Entry Catalyst kapp (M-1s-1) [a] Rate acceleration [b] 
1 none 0.0042±0.0007 1.0 
2 Cu2+ 0.051±0.003 12.1 
3 L5-Cu2+ 0.0071±0.0005 1.7 
4 L12-Cu2+ 0.029±0.004 6.9 
General conditions : D-A reactions between 1a (24 μM) and 2 at various concentrations 
(0.5-2.0 mM) were carried out with Cu2+(96 μM), L-Cu2+ composed of L(200μM) and 
Cu2+(96 μM), as well as in the absence of catalyst, in MOPS buffer (20 mM, pH 6.5), at 20 
°C. [a] The kapp values were determined from the initial rates according to the expression: 
kapp=Vinit/([1a]0·[2]0). [b] Rate acceleration is determined by the ratio of kapp, catalyzed / kapp, 
noncatalyzed. 
2.2.4 Substrate scope 
Then the scope of the reaction was investigated using the other chalcones 1b-f under 
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the optimized conditions. The different behavior of the catalyst based on L5 and L12 
was also evident for the reactions with varying substrates. In the presence of L12, the 
D-A reactions proceeded consistently well. Good conversions and high 
enantioselectivities, ranging from 83-91% ee, were achieved. Both the 
methoxy-substituted starting material 1b as well as the nitro-substituted derivative 1e 
led to excellent ee values (91% and 90% ee; Table 3, entries 1 and 4, respectively). 
The conversions produced by L5-Cu2+ with substrates 1e and 1f were much lower (< 
10%) than those obtained by L12-Cu2+ (Table 3, entries 4 and 5). The lower solubility 
of these substrates provides a possible explanation. In the case of 1b and 1d (Table 3, 
entries 1 and 3), moderate conversions were observed and similar ee values (≈ 60%) 
were achieved compared to substrate 1a. Substrate 1c gave a good conversion and 
diastereoselectivity (endo / exo = 96 / 4), although the ee value was slightly lower 
(Table 3, entry 2). These results demonstrate the importance of the composition of the 
peptide scaffold not only for asymmetric induction but also for chemical reactivity.[13] 










1a=C6H5   1b: R=p-CH3OC6H5   1c: R=m-CH3OC6H5   
1d: R=p-CH3C6H5   1e: R=p-NO2C6H5   1f: R=p-ClC6H5  
Entry Substrate 
Conversion[%] 
L5 / L12 
Endo:exo     
L5 / L12 
ee(endo) [%]             
L5 / L12 
1 1b 40 / 96 90:10/97:3 60 / 91 
2 1c 70 / 97 96:4 / 95:5 47 / 87 
3 1d 29 / 98 88:12/ 95:5 59 / 87 
4[a] 1e 8 / 69 n.d./ 90:10 n.d. / 90 
5[a] 1f 6 / 53 n.d. / 93:7 n.d. / 83 
General conditions : 1 (0.6 μmol), 2 (2 μL), Cu(NO3)2 (15% mol), L (30% mol) in MOPS 
buffer (20 mM, pH 6.5), for 3 days at 6 °C.  Data were obtained from the crude product on 
chiral HPLC. The ee values are averaged over two experiments and are reproducible within 





Current efforts are directed towards the elucidation of the structures of L5-Cu2+ and 
L12-Cu2+, which will give more insights into the origin of the high 
enantioselectivities. However, some preliminary structural requirements can be 
discussed in advance. In an initial experiment the copper catalyzed D-A reaction was 
carried out in the presence of tris-(2-carboxyethyl) phosphine (TCEP),[14] from which 
the intramolecular disulfide bridged cyclic peptides were reduced to their linear 
counterparts. Under this condition, racemic products 3a (3% ee) were obtained with 
either L5 or L12 indicating the crucial role of the intramolecular disulfide bond in 
providing a stable conformation of the peptide scaffold and its relation to the observed 
high enantioselectivities. In addition, alanine substituted L5 at the histidine position 
and N-terminal acetylated L12 were prepared to investigate the role of the binding 
sites within these two types of peptides. As expected, both changes caused complete 
loss of the enantioselectivities which represents an indirect proof for our anticipated 
anchoring positions. Nevertheless, more detailed characterizations are needed to draw 
a firm conclusion. 
The copper catalyzed D-A reaction described in our work was previously carried out 
in the presence of proteins and polypeptides. Hybrid catalysts containing serum 
albumins of different sources with more than 580 amino acids gave excellent ee 
values (85-98%).[2d] In efforts to decrease the size of these large scaffolds the small 
bovine pancreatic polypeptide (31 amino acids) was found to catalyze the D-A 
reaction with up to 83% ee when a non-natural amino acid was incorporated within 
the sequence for copper binding.[5e] In regard to these examples, we could 
significantly reduce the size of the peptide scaffold to only nine amino acids while 
maintaining comparable enantioselectivity and at the same time we do not need to 
incorporate any non-natural moiety like a phthalocyanine[2d] or pyridine.[5e] Compared 
to another example of asymmetric catalysis where the cyclic decapeptide gramicidin S 
was employed we achieved significantly higher ee values with our scaffold and did 
not require any modification of the peptide sequence.[5f] 




In conclusion, we have demonstrated a novel and versatile small peptide scaffold for 
Lewis acid catalyzed reactions. Due to its small size it can be fabricated very easily by 
standard solid phase synthesis methods in large quantities and no additional 
modifications or incorporation of non-natural amino acids is required. These attractive 
features are accompanied by a high enantioselectivity of the catalytic system in the 
copper catalyzed D-A reaction (up to 91% ee). Furthermore, we have given another 
proof that a confined fold is necessary to achieve enantiomeric enrichment compared 
to scaffolds exhibiting larger structural flexibility. In the future we will expand our 
investigations towards the screening of larger libraries based on the cyclic peptide to 
broaden the scope of reactions enabled by this scaffold.  
2.4 Experimental section 
2.4.1 General 
All UV-Vis spectra were measured on a JASCO V-630 spectrophotometer equipped 
with a temperature control accessory. 1H-NMR spectra were recorded on a Varian 400 
(1H, 400 MHz). Chemical shift (δ) are quoted in ppm with an internal reference 
tetramethylsilane. Enantiomeric excess was determined by High-Performance Liquid 
Chromatography (HPLC) analysis performed on a Shimadzu 10AD-VP instrument 
with the eluents of heptane and isopropanol (i-PrOH), using a Daicel Chiralcel ODH 
column, OD or AD column. Conversions were determined by HPLC and corrected for 
differences in extinction coefficient as reported in the literature[11e]. 
2.4.2 Materials 
Peptides (>95% purity) were purchased from CASLO ApS (Denmark) and used 
without further purification. All other chemicals were acquired from Acros or Sigma 
Aldrich and used without further purification. Substrates 1a-f were prepared 
following published procedures.[11] For all experiments, ultrapure water (18.2 MΩ) 




2.4.3 LC-MS analysis 
 
Figure 2.2. HPLC elugram and MALDI-TOF mass spectrum of L5 (a) and L12 (b) 
2.4.4 Optimization of reaction conditions 
















Figure 2.3. Enantiomeric excess of 3a at different peptide to Cu2+ ratios 
Table 2.4. Results of Diels-Alder reactions under various buffer conditions[a] 












1a 2 3a  
Entry buffer pH ee (endo) [%] 
L5 / L12 
1 20 mM MOPS 6.5 64 / 87 
2 50 mM MOPS 6.5 64 / 87 
3 100 mM MOPS 6.5 62 / 86 
4[b] 20 mM MES 6.5 61 / 84 
5 20 mM Na phosphate 6.5 59 / 77 
8[c] none 6.5 61 / 86 
[a] Reaction conditions were the same as described in the experimental section unless the 
buffer conditions. [b] MES = 2-(N-morpholino) ethanesulfonic acid. [c] pH was adjusted to 
6.5 with 1M NaOH solution. 
2.4.5 Kinetic measurements 
All kinetic measurements were performed as reported by Otto and Engberts [11a, 11b]. A 
typical procedure is as follows: the samples contained 96 μM Cu(NO3)2, 200 μM 
peptides, 24 μM azachalcone (1), and 0.5-2.0 mM of cyclopentadiene (2) with a total 
volume of 2.0 mL in 20 mM MOPS buffer at pH=6.5. The apparent second-order rate 
constant (kapp) was determined according to the following expression: 
kapp = d[A1]/dt·(d·(ε1 - ε3)·[1a]0·[2]0)-1 
In which d[A1]/dt is the slope of the absorption of 1 vs. time for the first 10% decrease 
of substrate conversion, d is the path length of the cuvette and ε1 and ε3 represent the 














Equation y = a + b*x
Adj. R-Square 0.9994
Value Standard Error
D Intercept 0.59537 7.16258E-6
D Slope -1.30533E-6 4.13515E-10













Equation y = a + b*x
Adj. R-Square 0.9999
Value Standard Error
D Intercept 0.61291 5.01558E-6
D Slope -2.2171E-6 2.89563E-10
 











Equation y = a + b*x
Adj. R-Square 0.99985
Value Standard Error
D Intercept 0.62103 8.93825E-6
D Slope -3.2222E-6 5.16028E-10












Equation y = a + b*x
Adj. R-Square 0.99676
Value Standard Error
D Intercept 0.65137 4.80333E-5
D Slope -3.76501E-6 2.77309E-9
 
Figure 2.4. Kinetic plots of D-A reaction in the absence of catalyst. 












Equation y = a + b*x
Adj. R-Square 0.99889
Value Standard Error
B Intercept 0.62784 2.05453E-5
B Slope -1.95123E-5 1.18609E-8










Equation y = a + b*x
Adj. R-Square 0.99937
Value Standard Error
B Intercept 0.65368 2.23654E-5
B Slope -2.81901E-5 1.29116E-8
 












Equation y = a + b*x
Adj. R-Square 0.99926
Value Standard Error
B Intercept 0.63272 3.62779E-5
B Slope -4.22188E-5 2.09433E-8











Equation y = a + b*x
Adj. R-Square 0.99961
Value Standard Error
B Intercept 0.60477 2.45549E-5
B Slope -4.82527E-5 2.13372E-8
 
Figure 2.5. Kinetic plots of D-A reaction catalyzed by Cu2+ ions without peptide 
ligands.  
kapp = 0.0042 M-1S-1 kapp = 0.0049 M-1S-1 (b) 
(a) 
kapp = 0.0036 M-1S-1 kapp = 0.0041 M-1S-1 
(d) (c) 
kapp = 0.053 M-1S-1 kapp = 0.074 M-1S-1 (b) (a) 
kapp = 0.046 M-1S-1 kapp = 0.053 M-1S-1 (d) (c) 
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Equation y = a + b*x
Adj. R-Square 0.99873
Value Standard Error
B Intercept 0.6861 6.32982E-6
B Slope -2.07345E-6 5.00591E-10














Equation y = a + b*x
Adj. R-Square 0.99987
Value Standard Error
D Intercept 0.69203 3.46412E-6
D Slope -3.7207E-6 2.99998E-10
 











Equation y = a + b*x
Adj. R-Square 0.99979
Value Standard Error
G Intercept 0.6804 6.54869E-6
G Slope -5.52886E-6 5.67126E-10












Equation y = a + b*x
Adj. R-Square 0.99988
Value Standard Error
D Intercept 0.6828 5.59078E-6
D Slope -6.92233E-6 5.80017E-10
 
Figure 2.6. Kinetic plots of D-A reaction catalyzed by L5-Cu2+.  











Equation y = a + b*x
Adj. R-Square 0.99818
Value Standard Error
B Intercept 0.65335 1.98755E-5
B Slope -1.4709E-5 1.14742E-8












Equation y = a + b*x
Adj. R-Square 0.9992
Value Standard Error
B Intercept 0.63294 1.63583E-5
B Slope -1.8315E-5 9.4437E-9
 













Equation y = a + b*x
Adj. R-Square 0.99926
Value Standard Error
B Intercept 0.63866 1.93993E-5
B Slope -2.24793E-5 1.11992E-8














Equation y = a + b*x
Adj. R-Square 0.99978
Value Standard Error
B Intercept 0.63978 1.20082E-5
B Slope -2.66047E-5 7.40105E-9
 
Figure 2.7. Kinetic plots of D-A reaction catalyzed by L12-Cu2+.  
kapp = 0.0070 M-1S-1 kapp = 0.0078 M-1S-1 (b) (a) 
kapp = 0.0066 M-1S-1 kapp = 0.0070 M-1S-1 (d) (c) 
kapp = 0.035 M-1S-1 kapp = 0.056 M-1S-1 (b) 
(a) 
kapp = 0.025 M-1S-1 kapp = 0.028 M





Standard procedure for peptide-Cu2+ complex catalyzed Diels-Alder reactions  
A catalyst solution composed of 1 mL of 200 μM peptide ligand and 96 μL of 1 mM 
Cu(NO3)2 was shaken for 30 minutes. An aliquot of a stock solution of dienophile in 
CH3CN (20 μLof 30 mM solution) was added and the mixture was cooled to 6 °C. 
The reaction was started by addition of the freshly distilled cyclopentadiene (2μl) and 
the mixture was shaken for 3 days at 6 °C, followed by extraction with diethyl ether 
(3×1 ml). After removal of the solvent, the ee of crude products were directly 
determined by HPLC on a chiral stationary phase. 
Standard procedure for the preparation of dienophiles 
A solution of 10% NaOH (2.5 ml) was added dropwise to a mixture of 
2-acetylpyridine (1g, 8.3 mmol) and benzaldehyde (0.95g, 9 mmol) in water (50 ml) 
with stirring, and was continued for 12h at room temperature. The precipitated solid 
was filtered off, washed several times with water and then purified by flash 
chromatography (n-hexane/ethyl acetate = 4/1) to give a pure product. 
1H NMR of dienophiles 1a-f 
3-phenyl-1-(2-pyridinyl)-2-penten-1-one (1a) 
1H-NMR (CDCl3, 400 MHz): 7.41 (m, 3H), 7.48 (m, 1H), 7.74 (m, 2H), 7.89 (m, 1H), 
7.94 (d, 1H, J = 16.0 Hz), 8.19 (d, 1H, J = 8.0 Hz), 7.94 (dd, 1H, J = 16.0 Hz, J = 1.2 
Hz), 8.74 (m, 1H). 
3-(4-methoxy-phenyl)-1-(2-pyridinyl)-2-penten-1-one (1b) 
1H-NMR (CDCl3, 400 MHz): 3.78 (s, 3H), 6.86 (d, 2H, J = 8.8 Hz), 7.40 (m, 1H), 
7.62 (d, 2H, J = 8.8 Hz), 7.80 (t, 1H, J = 7.6 Hz), 7.85 (d, 1H, J = 16.0 Hz), 8.10 (s, 
1H), 8.11 (dd, 1H, J = 16.0 Hz, J = 1.2 Hz), 8.66 (m, 1H). 
3-(3-methoxy-phenyl)-1-(2-pyridinyl)-2-penten-1-one (1c) 
1H-NMR (CDCl3, 400 MHz): 3.78 (s, 3H), 6.96 (m, 1H), 7.31 (m, 3H), 7.48 (m, 1H), 
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7.87 (m, 2H), 8.18 (t, 1H, J = 7.2 Hz), 8.74 (m, 1H). 
3-(4-methyl-phenyl)-1-(2-pyridinyl)-2-penten-1-one (1d) 
1H-NMR (CDCl3, 400 MHz): 2.38 (s, 3H), 7.22 (d, 2H, J = 8.0 Hz), 7.47 (m, 1H), 
7.62 (d, 2H, J = 8.4 Hz), 7.86 (m, 1H), 7.93 (d, 1H, J = 16.0 Hz), 8.18 (d, 1H, J = 8.0 
Hz), 8.25 (d, 1H, J = 16.0 Hz), 8.74 (m, 1H). 
3-(4-nitro-phenyl)-1-(2-pyridinyl)-2-penten-1-one (1e) 
1H-NMR (CDCl3, 400 MHz): 7.46 (m, 1H), 7.82 (m, 4H), 8.14 (d, 1H, J = 8.0 Hz), 
8.21 (d, 2H, J = 8.0 Hz), 8.36 (d, 1H, J = 16.0 Hz), 8.69 (m, 1H). 
3-(4-chloro-phenyl)-1-(2-pyridinyl)-2-penten-1-one (1f) 
1H-NMR (CDCl3, 400 MHz): 7.32 (d, 2H, J = 8.4 Hz), 7.42 (m, 1H), 7.59 (d, 2H, J = 
8.8 Hz), 7.81 (m, 2H), 8.12 (d, 1H, J = 8.0 Hz), 8.21 (d, 1H, J = 16.0 Hz), 8.67 (m, 
1H). 
1H NMR of dienophiles 3a-f 
(3-phenylbicyclo[2.2.1]hept-5-en-2-yl)(pyridin-2-yl)methanone (3a) 
1H-NMR (CDCl3, 400 MHz): 1.62 (m, 1H), 2.06 (d, 1H, J = 8.4 Hz), 3.09 (s, 1H), 
3.45 (d, 1H, J = 4 Hz), 3.54 (s, 1H), 4.53 (m, 1H), 5.82 (m, 1H), 6.49 (m, 1H), 7.16 
(m, 1H), 7.29 (m, 4H), 7.45 (m, 1H), 7.81 (m, 1H), 8.01 (m, 1H), 8.67 (m, 1H). ee 
was determined by HPLC analysis (Chiralcel-ODH, n-heptane/i-PrOH 98:2, 0.5 
ml/min). 
(3-(4-methoxyphenyl)bicyclo[2.2.1]hept-5-en-2-yl)(pyridin-2-yl)methanone (3b) 
1H-NMR (CDCl3, 400 MHz): 1.60 (d, 1H, J = 8.6 Hz), 2.06 (d, 1H, J = 9.0 Hz), 3.02 
(s, 1H), 3.05 (s, 1H), 3.38 (d, 1H, J = 4.2 Hz), 3.52 (s, 1H), 3.77 (s, 1H), 4.49 (m, 1H), 
5.81 (m, 1H), 6.48 (m, 1H), 6.82 (d, 2H, J = 8.2 Hz), 7.23 (d, 2H, J = 8.1 Hz), 7.44 (m, 
1H), 7.81 (m, 1H), 8.00 (d,1H, J = 7.8 Hz), 8.67 (m, 1H). ee was determined by 





1H-NMR (CDCl3, 400 MHz): 1.60 (d, 1H, J = 8.6 Hz), 2.06 (d, 1H, J = 9.0 Hz), 3.02 
(s, 1H), 3.05 (s, 1H), 3.38 (d, 1H, J = 4.2 Hz), 3.52 (s, 1H), 3.77 (s, 1H), 4.49 (m, 1H), 
5.81 (m, 1H), 6.48 (m, 1H), 6.82 (d, 2H, J = 8.2 Hz), 7.23 (d, 2H, J = 8.1 Hz), 7.44 (m, 
1H), 7.81 (m, 1H), 8.00 (d,1H, J = 7.8 Hz), 8.67 (m, 1H). ee was determined by 
HPLC analysis (Chiralcel-ODH, n-heptane/i-PrOH 99:1, 0.5 ml/min). 
(pyridin-2-yl(3-p-tolylbicyclo[2.2.1]hept-5-en-2-yl)methanone (3d) 
1H-NMR (CDCl3, 400 MHz): 1.61 (dd, 1H, J = 5.2, 6.8 Hz), 2.06 (d, 1H, J = 8.4 Hz), 
2.30 (s, 3H), 3.05 (s, 1H), 3.41 (d, 1H, J = 4.8 Hz), 3.53 (s, 1H), 4.52 (dd, 1H, J = 3.6, 
5.2 Hz), 5.81 (dd, 1H, J = 2.8, 5.6 Hz), 6.49 (dd, 1H, J = 3.2, 5.6 Hz), 7.09 (d, 2H, J = 
8.0 Hz), 7.21 (d, 2H, J = 8.0 Hz), 7.39 (m, 1H), 7.81 (m, 1H), 8.01 (d, 1H, J = 8.0 Hz), 
8.67 (d, 1H, J = 4.4 Hz). ee was determined by HPLC analysis (Chiralcel-ODH, 
n-heptane/i-PrOH 98:2, 0.5 ml/min). 
(3-(4-nitrophenyl)bicyclo[2.2.1]hept-5-en-2-yl)(pyridin-2-yl)methanone (3e) 
1H-NMR (CDCl3, 400 MHz): 1.67 (d, 1H, J = 8.5 Hz), 2.01 (d, 1H, J = 8.8 Hz), 3.13 
(s, 1H), 3.54 (d, 1H, J = 4.2 Hz), 3.61 (s, 1H), 4.47 (m, 1H), 5.87 (m, 1H), 6.49 (m, 
1H), 7.46 (m, 3H), 7.85 (m, 1H), 8.02 (d, 1H, J = 7.7 Hz), 8.13 (d, 2H, J = 8.2 Hz), 
8.66 (m, 1H). ee was determined by HPLC analysis (Chiralcel-AD, n-heptane/i-PrOH 
90:10, 1.0 ml/min). 
(3-(4-chlorophenyl)bicyclo[2.2.1]hept-5-en-2-yl)(pyridin-2-yl)methanone (3f) 
1H-NMR (CDCl3, 400 MHz): 1.67 (d, 1H, J = 8.5 Hz), 2.01 (d, 1H, J = 8.8 Hz), 3.13 
(s, 1H), 3.54 (d, 1H, J = 4.2 Hz), 3.61 (s, 1H), 4.47 (m, 1H), 5.87 (m, 1H), 6.49 (m, 
1H), 7.46 (m, 3H), 7.85 (m, 1H), 8.02 (d, 1H, J = 7.7 Hz), 8.13 (d, 2H, J = 8.2 Hz), 
8.66 (m, 1H). ee was determined by HPLC analysis (Chiralcel-ODH, 
n-heptane/i-PrOH 98:2, 0.5 ml/min). 
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